Theralase Technologies (CVE:TLT) Shares Down 3%

Theralase Technologies Inc. (CVE:TLT) was down 3% on Friday . The company traded as low as C$0.16 and last traded at C$0.16. Approximately 65,575 shares were traded during trading, a decline of 49% from the average daily volume of 128,920 shares. The stock had previously closed at C$0.17.

Theralase Technologies Trading Down 3.0 %

The company has a market capitalization of C$37.62 million, a P/E ratio of -8.00 and a beta of 1.66. The company has a debt-to-equity ratio of 25.07, a current ratio of 1.22 and a quick ratio of 3.40. The business’s 50-day moving average price is C$0.19 and its two-hundred day moving average price is C$0.19.

Theralase Technologies (CVE:TLT) last posted its earnings results on Wednesday, March 27th. The company reported C($0.01) earnings per share (EPS) for the quarter. The business had revenue of C$0.36 million during the quarter. As a group, analysts forecast that Theralase Technologies Inc. will post -0.05 EPS for the current fiscal year.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.